• Skip to main content
  • Es
  • En
Linkedin
  • By Phases
    • Preclinical and R&D
      • Biomarkers Analysis
      • Immunogenicity Assay
      • Metabolomics
      • Nucleic Acid Bioanalysis & Gene Therapy
      • Pharmacokinetic Analysis (PK/PD)
      • Regulated Impurities
      • Analytical Method Development, Validation & Transfer
      • Oligonucleotides
      • Peptide and Amino Acid Analysis
      • Protein and Biologics Characterization
      • Protein Analysis
    • CMC and QC
      • Biosimilar Services
      • Microbiology Control
      • QC Testing
      • Vaccine Analysis
      • Metabolomics
      • Nucleic Acid and Gene Therapy
      • Oligonucleotides
      • Peptide and Amino Acid Analysis
      • Protein Analysis
      • Regulated Impurities
      • Analytical Method Development, Validation & Transfer
  • By Molecules
    • Small Molecule
    • TIDES
    • Biologics
    • Advanced Therapies
  • About us
    • AMSbiopharma
    • Innovation
    • Quality
    • Careers
  • News
  • Contact
  • By Phases
    • Preclinical and R&D
      • Biomarkers Analysis
      • Immunogenicity Assay
      • Metabolomics
      • Nucleic Acid Bioanalysis & Gene Therapy
      • Pharmacokinetic Analysis (PK/PD)
      • Regulated Impurities
      • Analytical Method Development, Validation & Transfer
      • Oligonucleotides
      • Peptide and Amino Acid Analysis
      • Protein and Biologics Characterization
      • Protein Analysis
    • CMC and QC
      • Biosimilar Services
      • Microbiology Control
      • QC Testing
      • Vaccine Analysis
      • Metabolomics
      • Nucleic Acid and Gene Therapy
      • Oligonucleotides
      • Peptide and Amino Acid Analysis
      • Protein Analysis
      • Regulated Impurities
      • Analytical Method Development, Validation & Transfer
  • By Molecules
    • Small Molecule
    • TIDES
    • Biologics
    • Advanced Therapies
  • About us
    • AMSbiopharma
    • Innovation
    • Quality
    • Careers
  • News
  • Contact

New update for the ICH Q2 (R2) guidance on Analytical Process Validation

Posted on: 05/07/2024 Last updated on: 30/09/2025 Written by: amsbiowp
As planned for months, the draft ICH Q14 Guideline for AQbD Method Development and the draft ICH Q2 (R2) Guideline for Analytical Process Validation were published at the end of 2023. Both were developed over the past year and come…
Continue reading “New update for the ICH Q2 (R2) guidance on Analytical Process Validation”…

Contact us

If you are interested in working with us then please drop us a line, we would love to hear from you.

Rúa do Vidro, 117D, Parcelas 3-6 27003 – Lugo – Spain

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Subscribe to our newsletter

Stay informed with the latest news, updates, exclusive content, insightful articles, and important event announcements.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • R&D and Preclinical
    • Bioanalysis and biomarkers​
    • Metabolomics
  • Quality Control
    • Regulated Impurities / GMP
    • Analytical Method Development / GMP
    • Peptide and Amino Acid Analysis / Non-GLP
    • Oligonucleotides / Non-GLP
    • ICP-MS Analysis
    • Quality Control (QC) Testing / GMP
    • Microbiology
    • Medical cannabis
  • About us
    • AMSbiopharma
    • Innovation
    • Careers
  • News
  • Contact us
  • R&D and Preclinical
    • Bioanalysis and biomarkers​
    • Metabolomics
  • Quality Control
    • Regulated Impurities / GMP
    • Analytical Method Development / GMP
    • Peptide and Amino Acid Analysis / Non-GLP
    • Oligonucleotides / Non-GLP
    • ICP-MS Analysis
    • Quality Control (QC) Testing / GMP
    • Microbiology
    • Medical cannabis
  • About us
    • AMSbiopharma
    • Innovation
    • Careers
  • News
  • Contact us
  • Cookies Policy
  • Privacy Policy
  • Legal Notice
  • Cookies Policy
  • Privacy Policy
  • Legal Notice
Linkedin

AMSbiopharma a company of AMSlab – All rights reserved © 2024 | Made with love by ingenyus*